Business
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Recent Publication and Patent Application Referencing Apabetalone Support its Continued De...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nRecent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, May 23, 2017\n\n\n\nNature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates \n\n\n\nCALGARY, May 23, 2017 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX: RVX) today highlighted two additional works involving its lead drug, apabetalone, one recently published by third party academics and one in the form of a patent application by Pfizer Inc. (Pfizer).  The publication, titled \"Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD,\" is published in the prominent journal Nature Reviews Nephrology. This article describes the mechanisms that link Alkaline Phosphatase (ALP) to vascular calcification, inflammation, and cardiovascular disease. The Pfizer patent application was filed for the purpose of protecting their invention of using BET-family bromodomain inhibitors as a method of increasing frataxin in the treatment of patients with Friedreich's ataxia. Resverlogix' apabetalone, a BET bromodomain inhibitor, is specifically listed in Pfizer's patent. The patent describes the ataxia as a rare regressive inherited disease characterized by progressive damage to the nervous system and movement problems. \n\n\"We welcome the attention drawn to Resverlogix and apabetalone from significant industry groups such as Nature Reviews Nephrology and Pfizer. Due to the dramatic growth of BET Bromodomain publications over the past decade, it is not surprising that our advanced Phase 3 compound, apabetalone, is now drawing expanded attention from the global academic and pharmaceutical communities,\" stated Donald McCaffrey, President and Chief Executive Officer.\n\nDiscussion on ALP and Cardiovascular Disease in Chronic Kidney Disease (CKD)\n\nIn the May, 2017 edition, Nature Reviews Nephrology published an article titled: \"Alkaline phosphatase:...